• 1. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 2. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

Introduction to 2(1H)-Pyrimidinone, hydrazone, monohydrochloride (CAS No. 863652-26-0)

2(1H)-Pyrimidinone, hydrazone, monohydrochloride, identified by its Chemical Abstracts Service (CAS) number 863652-26-0, is a compound of significant interest in the field of pharmaceutical chemistry and medicinal biology. This heterocyclic derivative has garnered attention due to its unique structural properties and potential biological activities, making it a valuable scaffold for the development of novel therapeutic agents. The compound belongs to the hydrazones class, which are known for their versatility in drug design due to their ability to form stable complexes with various biomolecules.

The molecular structure of 2(1H)-Pyrimidinone, hydrazone, monohydrochloride consists of a pyrimidinone core linked to a hydrazine moiety, with the addition of a monohydrochloride salt form to enhance solubility and bioavailability. This structural configuration allows for multiple interactions with biological targets, including enzymes and receptors, which are pivotal in modulating cellular processes. The pyrimidinone ring is a common motif in bioactive molecules, often found in nucleoside analogs and antiviral agents, underscoring the compound's potential therapeutic relevance.

In recent years, there has been a surge in research focused on developing small-molecule inhibitors targeting various disease pathways. 2(1H)-Pyrimidinone, hydrazone, monohydrochloride has emerged as a promising candidate in this endeavor. Its hydrazine group can engage in hydrogen bonding and coordinate with metal ions, which are essential for numerous enzymatic reactions. This property makes it an attractive scaffold for designing molecules that can interfere with disease-causing mechanisms.

One of the most compelling aspects of 2(1H)-Pyrimidinone, hydrazone, monohydrochloride is its potential application in oncology research. Studies have demonstrated that hydrazones can exhibit inhibitory effects on kinases and other enzymes involved in cancer cell proliferation. The pyrimidinone core further enhances its binding affinity by forming stable hydrogen bonds with key residues in the active sites of target proteins. Preliminary computational studies have suggested that this compound may interact with enzymes such as tyrosine kinases, which are overexpressed in many solid tumors.

Furthermore, the pharmacokinetic profile of 2(1H)-Pyrimidinone, hydrazone, monohydrochloride has been evaluated to assess its suitability for clinical development. The monohydrochloride salt form improves water solubility, facilitating intravenous administration and enhancing drug delivery efficiency. In vitro studies have shown that this compound exhibits moderate bioavailability and a reasonable half-life upon systemic administration. These findings are crucial for determining its feasibility as an oral or injectable therapeutic agent.

The synthesis of 2(1H)-Pyrimidinone, hydrazone, monohydrochloride involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. The key step involves the condensation of a hydrazine derivative with a pyrimidinone precursor under acidic conditions. The resulting hydrazone intermediate is then converted into the monohydrochloride salt by treating it with hydrochloric acid. Advanced synthetic techniques such as flow chemistry have been explored to optimize these reactions and improve scalability.

Advances in spectroscopic methods have also contributed to a deeper understanding of the structural properties of 2(1H)-Pyrimidinone, hydrazone, monohydrochloride. Techniques such as nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography have provided detailed insights into its molecular conformation and interactions with biological targets. These structural insights are invaluable for rational drug design and for predicting potential side effects.

Preclinical studies have begun to explore the therapeutic potential of 2(1H)-Pyrimidinone, hydrazone, monohydrochloride in various disease models. Initial results suggest that it may exhibit anti-inflammatory properties by modulating cytokine production and inhibiting inflammatory pathways. Additionally, its ability to interact with metal ions has led researchers to investigate its potential as an antimicrobial agent against resistant bacterial strains.

The development of 2(1H)-Pyrimidinone, hydrazone, monohydrochloride is part of a broader effort to discover novel therapeutics using computational chemistry and high-throughput screening technologies. By leveraging these tools, researchers can rapidly identify promising candidates for further investigation. The integration of machine learning algorithms into drug discovery pipelines has accelerated the process by predicting molecular properties and optimizing lead compounds.

The future prospects for 2(1H)-Pyrimidinone, hydrazone, monohydrochloride are promising but depend on successful translation from preclinical to clinical studies. Collaborative efforts between academic institutions and pharmaceutical companies are essential to advance this compound through regulatory approval stages. Regulatory agencies will scrutinize data from preclinical trials before allowing human testing but will also recognize innovative approaches that demonstrate safety and efficacy.

In conclusion,2(1H)-Pyrimidinone, hydrazone, and its monohydrochloride salt (CAS No. 863652-26-0) represent an exciting area of research with significant therapeutic implications across multiple diseases including cancer, inflammation,and infectious disorders.* Its unique structural features,*potential biological activities,*and favorable pharmacokinetic properties make it*an attractive candidate*for further exploration.*Continued*research*and*development*will be crucial*to unlock its full potential*and bring novel treatments*to patients worldwide.*

• 19868-02-1(pyrimidin-2-amine hydrochloride)
• 1609406-80-5(2-Hydrazinopyrimidine Hydrate)
• 823-90-5(5-chloro-2-hydrazinylpyrimidine)
• 97460-00-9(2-Pyrimidinamine,N-nitroso-)
• 7504-94-1(2-hydrazinylpyrimidine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)